Future research on the P2X7 receptor in Chagas disease should integrate therapeutic innovation with advanced methodological strategies, involving the development of dual‐action molecules, such as triazole derivatives, which combine antiparasitic activity against T. cruzi with inhibition of P2X7‐mediated pore formation, thereby attenuating inflammation [71, 74]. This evidence concerns the gene P2RX7 and Chagas disease.